This Article Full Text Full Text (PDF) Other Versions of this Article: IAI.01673-06v1 75/4/1794    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ekström, N. Search for Related Content PubMed PubMed Citation Articles by Ekström, N.

 Previous Article  |  Next Article 

Infection and Immunity, April 2007, p. 1794-1800, Vol. 75, No. 4
0019-9567/07/$08.00+0     doi:10.1128/IAI.01673-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Functional Antibodies Elicited by Two Heptavalent Pneumococcal Conjugate Vaccines in the Finnish Otitis Media Vaccine Trial

Nina Ekström,^* Merja Väkeväinen, Jouko Verho, Terhi Kilpi, Helena Käyhty, and the FinOM Study Group

National Public Health Institute, Helsinki, Finland

Received 19 October 2006/ Returned for modification 17 November 2006/ Accepted 17 January 2007

In the Finnish Otitis Media Vaccine Trial, the now-licensed pneumococcal conjugate vaccine containing polysaccharides conjugated to protein CRM₁₉₇ (PncCRM) and the experimental pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine (PncOMPC), showed similar efficacy profiles against acute otitis media despite different antibody concentrations in sera. We now report the opsonophagocytic activities (OPA) in these sera. OPA, antibody concentration, and avidity for serotypes 6B, 19F, and 23F were determined in sera of infants who received either pneumococcal conjugate (PCV) or control vaccine at 2, 4, and 6 months of age and either the homologous or pneumococcal polysaccharide vaccine at 12 months of age. OPA varied by vaccine and serotype. The majority of PCV recipients had positive OPA after the fourth dose, while OPA was undetectable in the control group. Coinciding with the efficacy data, the concentration of antibodies required for 50% killing was low for 6B and high for 19F for both PCVs. Contradictory to the efficacy data, PncOMPC induced lower functional capacity to 23F than PncCRM. OPA correlated with antibody concentration, while avidity and functional capacity of antibodies showed no correlation. The OPA data provide valuable additional information for serotype-specific differences in protection and when evaluating serotype-specific immunogenicity and should thus be considered when defining serological correlates of protection.

Published ahead of print on 29 January 2007.

Editor: D. L. Burns

Present address: University of Helsinki, Helsinki, Finland.